核医学用ソフトウェア市場 – 2030年までの世界予測

• このレポートでは、ソフトウェアの種類、ワークフロー、統合の複雑さ、ソフトウェア ライセンス モデル、収益モデル、用途、治療領域、技術の成熟度、エンド ユーザー、および地域に基づいて、核医学ソフトウェア市場を調査します。
• このレポートでは、市場の成長に影響を与える要因（推進要因、制約、機会、課題など）を分析します。
• このレポートでは、利害関係者にとっての市場の機会と課題を評価し、市場リーダーの競争環境の詳細を提供します。
• このレポートでは、マイクロマーケットの成長傾向、見通し核医学ソフトウェア市場全体への貢献について調査しています。
• このレポートでは、5 つの主要地域に関して市場セグメントの収益を予測しています。

The nuclear medicine software market was valued at USD 970.03 million in 2025 and is estimated to reach USD 1,491.6 million by 2030, registering a CAGR of 9.0% during the forecast period. Growth in the nuclear medicine software market is being influenced by a convergence of clinical and technological advancements, along with favorable regulatory and reimbursement frameworks in developed and developing nations. These technological advancements are significantly transforming how nuclear medicine imaging and radiopharmaceutical therapies are delivered. Key factors driving growth include the increasing demand for accurate image analysis, PACS integration, dosimetry, treatment planning, advanced analytics, and reporting. In addition to the growing demand in the diagnostic imaging segment, nuclear medicine therapeutic applications are seeing an increase in the adoption rates of theranostics. Leading market players are increasingly integrating their solutions with AI-powered tools for tumor segmentation and automated reporting, thereby enhancing diagnostic accuracy and workflow efficiency. The pharmaceutical and life sciences sectors are fueling the demand for advanced nuclear medicine software solutions due to the expanding pipeline of radiopharmaceuticals. Furthermore, the growing transition towards cloud-native PACS integration and remotely accessible solutions is promoting the development of advanced software solutions. However, the growth of this market is moderately restrained due to challenges arising from data security, inadequate infrastructure, and radiation exposure.

核医学用ソフトウェア市場は2025年に9億7,003万米ドルと評価され、2030年には14億9,160万米ドルに達すると予測されており、予測期間中に9.0%の年平均成長率（CAGR）を記録します。核医学用ソフトウェア市場の成長は、臨床的進歩と技術的進歩の融合、そして先進国および発展途上国における好ましい規制および保険償還の枠組みの影響を受けています。これらの技術進歩は、核医学イメージングおよび放射性医薬品治療の提供方法を大きく変革しています。成長を牽引する主な要因としては、正確な画像解析、PACS統合、線量測定、治療計画、高度な分析、レポート作成に対する需要の高まりが挙げられます。診断画像分野での需要増加に加え、核医学治療アプリケーションではセラノスティクスの採用率が増加しています。大手市場プレーヤーは、腫瘍セグメンテーションや自動レポート作成のためのAI搭載ツールとソリューションの統合を進めており、診断精度とワークフロー効率を向上させています。製薬・ライフサイエンス分野では、放射性医薬品のパイプライン拡大に伴い、高度な核医学ソフトウェアソリューションの需要が高まっています。さらに、クラウドネイティブのPACS統合やリモートアクセス可能なソリューションへの移行が進み、高度なソフトウェアソリューションの開発が促進されています。しかし、データセキュリティ、インフラの不備、放射線被ばくといった課題により、この市場の成長はやや抑制されています。

“Cloud-native platforms are expected to register the fastest growth over the forecast period.”

The lucrative growth of cloud-native platforms is attributed to the increasing demand for remote access, interoperability, and scalability across healthcare systems. Nuclear medicine is rapidly evolving through multi-center collaborations and AI-powered analytics, driving the need for cloud-native solutions. These platforms enable real-time data sharing, faster software updates, and enhanced cybersecurity features. Furthermore, healthcare systems are transitioning towards a value-based care approach, in which cloud-developed infrastructure supports integrated decision-making, thereby enhancing overall patient care. Moreover, the adoption of advanced nuclear medicine workflows requires cloud-based software platforms that can synchronize imaging and treatment planning. Some companies offering cloud-native platforms include Sectra’s Cloud Imaging Platform and Intelerad’s IntelePACS Cloud. These solutions support PET/SPECT viewing and reporting, seamlessly integrating with AI modules for remote accessibility.

“The subscription-based/Software-as-a-service (SaaS) models segment held the largest share of the nuclear medicine software market in 2024.”

The subscription-based Software-as-a-Service (SaaS) model segment dominates the software licensing segment in the nuclear medicine software market in 2024. This dominance is due to the lower upfront costs, flexibility, and cloud-based deployments offered by this model. Healthcare providers, life sciences companies, and research institutes are increasingly shifting from traditional perpetual licensing models because of the high capital expenditures and limited scalability associated with them. SaaS models provide regular software updates with predictable operational costs and seamlessly integrate with cloud-native PACS and radiology systems, thereby supporting hospitals and imaging centers in modernizing their nuclear imaging workflows. With the expansion of multi-site imaging networks, SaaS platforms enable centralized data access, interoperable workflows, and remote access diagnostics. Some of the leading market players offering their solutions through subscription-based SaaS models are GE Healthcare and Siemens Healthineers.

“North America market accounts for the largest share in the nuclear medicine software market in 2024.”

The North American market dominated the nuclear medicine software sector in 2024, due to its advanced healthcare infrastructure, increasing adoption of hybrid imaging systems, and strong regulatory support for radiopharmaceutical-based diagnostics and therapeutics. Additionally, the significant presence of market leaders such as GE Healthcare and Siemens Healthineers contributes to the growth of the North American market. In contrast, the Asia Pacific market is expected to register the fastest growth rate over the forecast period. This growth is attributed to rising public and private investments in precision medicine, an escalating disease burden from cancer and cardiovascular diseases, and advancements in infrastructure across China, India, Japan, Australia, and South Korea. Furthermore, the region is experiencing rapid adoption of personalized dosimetry and theranostics, alongside increasing partnerships between local hospitals and globally established companies. Growing patient awareness, rising healthcare IT expenditure, and the increasing adoption of AI-based imaging solutions are further boosting growth in the Asia Pacific market.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the nuclear medicine software marketplace.

The breakdown of primary participants is as mentioned below:

• By Company Type – Tier 1 (31%), Tier 2 (31%), and Tier 3 (28%)
• By Designation – C-level Executives (44%), Director-level (31%), and Managers (25%)
• By Region – North America (45%), Europe (28%), Asia Pacific (20%), Latin America (4%), and Middle East & Africa (3%)

Key Players in the Nuclear Medicine Software Market

Prominent players in the nuclear medicine software market include include GE HealthCare (MIM Software Inc.)(US), Siemens Healthineers AG(Germay), Koninklijke Philips N.V. (Netherlands), Lantheus Holdings, Inc. (EXINI Diagnostics AB)(US), Brainlab AG(Germany),  Mirada Medical(UK), DOSIsoft SA(France), Bracco Group (Italy), Hermes Medical Solutions (Sweden), INVIA, LLC (US), Mediso Ltd. (Hungary), Canon Medical Systems Corporation (Japan), LabLogic Systems Ltd. (UK), Mirion Technologies (ec2 Software Solutions)(US), COMECER S.p.A.(Italy), RaySearch Laboratories(Sweden), UltraSPECT Inc. (US), Sectra AB (Sweden), Agfa-Gevaert Group (Belgium), Perceptive(UK).

Players adopted both organic and inorganic growth strategies, including product launches and enhancements, as well as investments, partnerships, collaborations, joint ventures, funding, acquisitions, expansions, agreements, contracts, and alliances. These strategies aimed to increase their offerings, meet the unmet needs of customers, boost profitability, and expand their presence globally market.

The study includes an in-depth competitive analysis of these key players in the nuclear medicine software market, with their company profiles, recent developments, and key market strategies.

Research Coverage

• The report studies the nuclear medicine software market based on software type, workflow, integration complexity, software licensing model, revenue model, application, therapeutic area, technology maturity, end user, and region.
• The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
• The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
• The report studies micromarkets with respect to their growth trends, prospects, and contributions to the total nuclear medicine software market.
• The report forecasts the revenue of market segments with respect to five major regions.

Reasons to Buy the Report

The report can help established firms, as well as new entrants/smaller firms, gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the five strategies mentioned below.

This report provides insights into the following pointers:

Analysis of key drivers (increasing demand for early and accurate diagnostics, growing focus on personalized medicine, integration of automated dosimetry tools, growing prevalence of chronic diseases and subsequent increase in clinical trials, effective monitoring of nuclear medicine software), restraints (high cost of imaging equipment, data privacy and security concerns, shortage of skilled professionals, interpolability issues), opportunities (infrastructure development, increased healthcare IT expenditure, data privacy and regulatory reforms), and challenges (compliance requirements, low penetration of advanced imaging devices, underdeveloped radiopharmcy ecosysytem, economic and financial barriers) influencing the industry macrodynamics of nuclear medicine software market.

• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the nuclear medicine software market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of nuclear medicine software across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the nuclear medicine software market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the nuclear medicine software market.

Table of Contents

1               INTRODUCTION              42

1.1           STUDY OBJECTIVES       42

1.2           MARKET DEFINITION   42

1.3           STUDY SCOPE   43

1.3.1        MARKET SEGMENTATION & REGIONAL SCOPE 43

1.3.2        YEARS CONSIDERED      45

1.4           CURRENCY CONSIDERED            45

1.5           STAKEHOLDERS               46

1.6           LIMITATIONS    46

2               RESEARCH METHODOLOGY       47

2.1           RESEARCH APPROACH  47

2.1.1        SECONDARY RESEARCH                47

2.1.1.1    Key data from secondary sources       48

2.1.2        PRIMARY RESEARCH       49

2.1.2.1    Primary sources    49

2.1.2.2    Key data from primary sources           50

2.1.2.3    Breakdown of primaries      50

2.1.2.4    Insights from primary experts             51

2.2           RESEARCH METHODOLOGY DESIGN     51

2.3           MARKET SIZE ESTIMATION         52

2.4           MARKET BREAKDOWN & DATA TRIANGULATION                 57

2.5           MARKET SHARE ESTIMATION    57

2.6           STUDY ASSUMPTIONS  58

2.7           RESEARCH LIMITATIONS             58

2.7.1        METHODOLOGY-RELATED LIMITATIONS           58

2.8           RISK ASSESSMENT           58

3               EXECUTIVE SUMMARY  59

4               PREMIUM INSIGHTS       66

4.1           OVERVIEW OF NUCLEAR MEDICINE SOFTWARE MARKET               66

4.2          ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET,

BY COUNTRY & INTEGRATION COMPLEXITY     67

4.3           GEOGRAPHIC SNAPSHOT OF NUCLEAR MEDICINE SOFTWARE MARKET       68

4.4           NUCLEAR MEDICINE SOFTWARE MARKET: REGIONAL MIX        68

4.5           NUCLEAR MEDICINE SOFTWARE MARKET: DEVELOPED VS. EMERGING ECONOMIES       69

5               MARKET OVERVIEW       70

5.1           INTRODUCTION              70

5.2           MARKET DYNAMICS       70

5.2.1        DRIVERS               71

5.2.1.1    Rising global disease prevalence        71

5.2.1.2    Surge in AI-powered theranostics      72

5.2.1.3    Adoption of cloud-based platforms & mobile/remote diagnostics                 72

5.2.1.4    Radiopharmaceutical supply chain visibility & radiopharmaceutical software             72

5.2.1.5    Expansion of personalized medicine in nuclear applications                 73

5.2.2        RESTRAINTS      73

5.2.2.1    High acquisition & total cost of ownership       73

5.2.2.2    Regulatory & approval delays with AI integration           74

5.2.2.3    Integration & interoperability challenges         74

5.2.3        OPPORTUNITIES              75

5.2.3.1    Precision & predictive dosimetry       75

5.2.3.2    Expansion of tele-nuclear medicine networks & mobile access                 75

5.2.4        CHALLENGES    75

5.2.4.1    Lack of technical expertise  75

5.2.4.2    Regulatory uncertainties     76

5.3           TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES       76

5.4           INDUSTRY TRENDS         77

5.4.1        OVERVIEW OF USE CASES            77

5.4.2        INTEGRATION OF ARTIFICIAL INTELLIGENCE AND ADVANCED ANALYTICS                79

5.4.3        SHIFT TOWARD HYBRID AND MULTI-MODALITY IMAGING SOLUTIONS   79

5.5           ECOSYSTEM ANALYSIS  79

5.6           SUPPLY CHAIN ANALYSIS             82

5.7           TECHNOLOGY ANALYSIS             83

5.7.1        KEY TECHNOLOGIES     83

5.7.1.1    SPECT/PET image reconstruction algorithms                83

5.7.1.2    Quantitative molecular imaging tools                84

5.7.1.3    Radiopharmaceutical dosimetry software         84

5.7.1.4    Artificial intelligence and machine learning     84

5.7.1.5    Multi-modality fusion & co-registration engines             84

5.7.2        COMPLEMENTARY TECHNOLOGIES       84

5.7.2.1    DICOM AND HL7 integration engines           84

5.7.2.2    Theranostics workflow orchestration tools       85

5.7.2.3    Cloud-based PACS/archiving solutions            85

5.7.3        ADJACENT TECHNOLOGIES       85

5.7.3.1    Molecular imaging-omics integration tools      85

5.7.3.2    Blockchain             85

5.8           REGULATORY ANALYSIS               86

5.8.1        REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             86

5.8.2        REGULATORY ANALYSIS               88

5.9           PRICING ANALYSIS          91

5.9.1        INDICATIVE PRICE FOR NUCLEAR MEDICINE SOFTWARE, BY KEY PLAYER (2024)           91

5.9.2        INDICATIVE PRICE FOR NUCLEAR MEDICINE SOFTWARE, BY REGION (2024)   92

5.9.3        PRICING MODELS (QUALITATIVE)          93

5.10         PORTER’S FIVE FORCES ANALYSIS           93

5.10.1      THREAT OF NEW ENTRANTS      95

5.10.2      THREAT OF SUBSTITUTES          95

5.10.3      BARGAINING POWER OF BUYERS             95

5.10.4      BARGAINING POWER OF SUPPLIERS       95

5.10.5      INTENSITY OF COMPETITIVE RIVALRY 95

5.11         PATENT ANALYSIS          95

5.11.1      PATENT PUBLICATION TRENDS FOR NUCLEAR MEDICINE SOFTWARE SOLUTIONS         96

5.11.2      INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS            96

5.12         KEY STAKEHOLDERS & BUYING CRITERIA            98

5.12.1      KEY STAKEHOLDERS IN BUYING PROCESS           98

5.12.2      BUYING CRITERIA           99

5.13         END-USER ANALYSIS      99

5.13.1      UNMET NEEDS 99

5.13.2      END-USER EXPECTATIONS         100

5.14         KEY CONFERENCES & EVENTS, 2025–2026              101

5.14.1      NUCLEAR MEDICINE SOFTWARE MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2025–2026      101

5.15         CASE STUDY ANALYSIS 103

5.15.1      ENSURING PRECISION IN NUCLEAR MEDICINE WITH NATIONAL STANDARD TRACEABILITY 103

5.15.1.1  Case 1: Strengthening quality control and patient outcomes with ANSTO’s coordinated CRM program               103

5.15.2      STREAMLINING MULTI-MODALITY IMAGE FUSION FOR BETTER DIAGNOSTICS 104

5.15.2.1  Case 2: GE HealthCare’s Xeleris platform enhances multi-modality imaging at a leading academic medical center 104

5.15.3      SUPPORTING REMOTE CONSULTATIONS WITH CLOUD-BASED NUCLEAR MEDICINE ANALYSIS 104

5.15.3.1  Case 3: Sectra’s cloud-based solution empowers remote nuclear medicine consultations for regional hospitals  104

5.16         INVESTMENT & FUNDING SCENARIO     105

5.17         BUSINESS MODEL ANALYSIS      105

5.17.1      LICENSE-BASED BUSINESS MODELS       105

5.17.2      SUBSCRIPTION-BASED BUSINESS MODELS          105

5.17.3      SOFTWARE-AS-A-SERVICE (SAAS) BUSINESS MODELS                 106

5.17.4      PAY-PER-USE BUSINESS MODELS             106

5.17.5      FREEMIUM BUSINESS MODELS 106

5.17.6      INTEGRATED SERVICE AND SOFTWARE BUNDLE BUSINESS MODELS         106

5.18         IMPACT OF AI/GEN AI ON NUCLEAR MEDICINE SOFTWARE MARKET       106

5.18.1      KEY USE CASES 107

5.18.2      CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION         108

5.18.2.1  Case study 1: AI-based low-dose PET image reconstruction                 108

5.18.2.2  Case study 2: Dose-aware diffusion models for 3D low-dose PET                 108

5.18.3      IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS              109

5.18.3.1  Medical image analysis software        109

5.18.3.2  Radiology information systems          109

5.18.3.3  Clinical decision support systems      110

5.18.4      USER READINESS & IMPACT ASSESSMENT            110

5.18.4.1  User readiness       110

5.18.4.1.1                User A: Healthcare providers              110

5.18.4.1.2                User B: Pharmaceutical & biotechnology companies                 110

5.18.4.2  Impact assessment                110

5.18.4.2.1                User A: Healthcare providers              110

5.18.4.2.1.1            Implementation    110

5.18.4.2.1.2            Impact    111

5.18.4.2.2                User B: Pharmaceutical & biotechnology companies                 111

5.18.4.2.2.1            Implementation    111

5.18.4.2.2.2            Impact    111

5.19         IMPACT OF 2025 US TARIFFS ON NUCLEAR MEDICINE SOFTWARE MARKET       112

5.19.1      INTRODUCTION              112

5.19.2      KEY TARIFF RATES          113

5.19.3      PRICE IMPACT ANALYSIS             114

5.19.4      IMPACT ON COUNTRY/REGION                115

5.19.4.1  US           115

5.19.4.2  Europe   115

5.19.4.3  Asia Pacific            115

5.19.5      IMPACT ON END-USE INDUSTRIES          116

6               NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE              117

6.1           INTRODUCTION              118

6.2           IMAGE ACQUISITION & RECONSTRUCTION SOFTWARE                 119

6.2.1        ABILITY TO OPTIMIZE NUCLEAR IMAGING THROUGH AI-POWERED ACQUISITION AND RECONSTRUCTION SOFTWARE TO DRIVE MARKET 119

6.3           IMAGE ANALYSIS & QUANTIFICATION SOFTWARE                 120

6.3.1        AI INNOVATION, WORKFLOW OPTIMIZATION, AND PERSONALIZED CARE TRENDS TO SUPPORT GROWTH 120

6.4           WORKFLOW MANAGEMENT & ORCHESTRATION SOFTWARE         122

6.4.1        NEED FOR ADVANCING NUCLEAR MEDICINE THROUGH INTEGRATED WORKFLOW MANAGEMENT SOLUTIONS TO BOOST GROWTH            122

6.5           PACS INTEGRATION & DATA MANAGEMENT SOFTWARE         123

6.5.1        GROWING NEED FOR RADIOTRACER-AWARE ANALYTICS, COMPLIANCE, AND INTEROPERABILITY TO BOOST ADOPTION         123

6.6           REPORTING & DOCUMENTATION SOFTWARE   125

6.6.1        EXPANDING HEALTHCARE INVESTMENTS IN APAC AND MIDDLE EAST TO ACCELERATE ADOPTION OF REPORTING & DOCUMENTATION SOFTWARE 125

6.7           RADIOPHARMACEUTICAL MANAGEMENT SOFTWARE                 126

6.7.1        OPERATIONAL, CLINICAL, AND REGULATORY CATALYSTS TO DRIVE MARKET GROWTH            126

6.8           DOSIMETRY & TREATMENT PLANNING SOFTWARE                 128

6.8.1        PRECISION IMAGING AND AI-DRIVEN WORKFLOWS TO ADVANCE DOSIMETRY & TREATMENT PLANNING           128

6.9           QUALITY CONTROL & ASSURANCE SOFTWARE 129

6.9.1        HYBRID-IMAGING QA NEEDS, DIGITAL AUDIT READINESS, AND EDGE-BASED AI FOR OFFLINE ENVIRONMENTS TO FUEL GROWTH      129

6.10         AI & ADVANCED ANALYTICS SOFTWARE               130

6.10.1      ABILITY OF INTEGRATED AI ECOSYSTEMS TO REDEFINE NUCLEAR IMAGING EFFICIENCY TO SUPPORT MARKET               130

6.11         MOBILE & REMOTE ACCESS SOFTWARE                132

6.11.1      GROWING POPULARITY OF PORTABLE AND POINT-OF-CARE SCANNERS TO DRIVE MARKET DEMAND 132

7               NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW       134

7.1           INTRODUCTION              135

7.2           IMAGE ACQUISITION     135

7.2.1        ADVANCED INNOVATIONS TRANSFORMING IMAGE ACQUISITION INTO DYNAMIC, MULTI-FUNCTIONAL COMPONENTS TO DRIVE MARKET          135

7.3           DATA PROCESSING         136

7.3.1        OPTIMIZING CLINICAL INSIGHTS WITH INTELLIGENT DATA PROCESSING IN NUCLEAR MEDICINE WORKFLOWS TO SUPPORT GROWTH        136

7.4           REPORTING       138

7.4.1        PRECISION AND EFFICIENCY ASSOCIATED WITH AI-INTEGRATED REPORTING SOLUTIONS TO TRANSFORM MARKET               138

7.5           DATA MANAGEMENT    139

7.5.1        GROWING NEED FOR ADVANCED DATA MANAGEMENT SOLUTIONS TO STREAMLINE IMAGING WORKFLOWS TO DRIVE GROWTH             139

8               NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY      142

8.1           INTRODUCTION              143

8.2           STANDALONE SOLUTIONS          143

8.2.1        AVAILABILITY OF ROBUST STANDALONE SOLUTIONS TAILORED TO SPECIFIC IMAGING AND ANALYSIS NEEDS TO BOOST MARKET               143

8.3           INTEGRATED SOLUTIONS           145

8.3.1        ADVANTAGES SUCH AS REDUCED MANUAL STEPS AND IMPROVED DIAGNOSTIC ACCURACY TO DRIVE DEMAND                 145

8.4           CLOUD-NATIVE PLATFORMS     146

8.4.1        ABILITY OF CLOUD-NATIVE PLATFORMS TO DRIVE SCALABLE AND CONNECTED IMAGING IN NUCLEAR MEDICINE TO DRIVE MARKET         146

9               NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING 149

9.1           INTRODUCTION              150

9.2           PERPETUAL/TRADITIONAL LICENSES   150

9.2.1        GROWING DEMAND FOR PREDICTABLE LONG-TERM COSTS TO DRIVE ADOPTION     150

9.3           SUBSCRIPTION/SAAS LICENSES 152

9.3.1        ABILITY OF CLOUD-BASED SAAS SOLUTIONS TO ENHANCE IMAGING SCALABILITY AND EXPAND ACCESS TO FUEL GROWTH 152

9.4           USAGE-BASED LICENSES              153

9.4.1        ADVANTAGES SUCH AS SCALABLE ACCESS, REGULATORY COMPLIANCE, AND OPTIMIZED COSTS TO DRIVE DEMAND               153

9.5           ENTERPRISE AGREEMENTS         155

9.5.1        SEAMLESS DIGITAL TRANSFORMATION IN NUCLEAR MEDICINE THROUGH ENTERPRISE AGREEMENTS TO SUPPORT MARKET GROWTH          155

10            NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL 157

10.1         INTRODUCTION              158

10.2         SOFTWARE LICENSES    158

10.2.1      ADVANTAGES SUCH AS SCALABLE, AI-POWERED, AND COMPLIANT IMAGING SOLUTIONS TO DRIVE DEMAND                 158

10.3         MAINTENANCE & SUPPORT        160

10.3.1      RELIABLE DIAGNOSTICS AND MINIMIZED DOWNTIME ASSOCIATED WITH MAINTENANCE & SUPPORT SERVICES TO BOOST MARKET               160

10.4         PROFESSIONAL SERVICES            161

10.4.1      OPTIMIZING PHARMACY OPERATIONS THROUGH COMPREHENSIVE AUTOMATION SERVICES TO DRIVE GROWTH                 161

10.5         CLOUD SERVICES            163

10.5.1      ACCELERATING NUCLEAR MEDICINE TRANSFORMATION THROUGH CLOUD-DRIVEN IMAGING AND AI INTEGRATION TO BOOST MARKET   163

11            NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION   165

11.1         INTRODUCTION              166

11.2         DIAGNOSTICS   166

11.2.1      AUTOMATED IMAGE INTERPRETATION               168

11.2.1.1  Ability of AI-powered automated interpretation tools to streamline imaging workflows and reduce variability to boost adoption                 168

11.2.2      TUMOR SEGMENTATION & QUANTIFICATION  169

11.2.2.1  Advancing precision oncology through AI-powered tumor segmentation solutions to support market growth          169

11.3         THERAPEUTICS                170

11.3.1      PREDICTIVE ANALYTICS               171

11.3.1.1  Advantages such as enhanced dosimetry accuracy and improved clinical outcomes to drive growth      171

11.3.2      WORKFLOW OPTIMIZATION & QUALITY CONTROL                 172

11.3.2.1  Ability of workflow optimization and quality control solutions to enhance operational efficiency to boost market               172

11.3.3      PERSONALIZED DOSIMETRY CALCULATIONS    173

11.3.3.1  Optimized radiation delivery and standardized nuclear medicine workflows to drive demand 173

11.3.4      THERANOSTICS                174

11.3.4.1  Advantages such as real-time treatment optimization in nuclear medicine to drive popularity of theranostics    174

11.4         EMERGENCY & STAT WORKFLOWS          174

11.4.1      NEED TO ACCELERATE CRITICAL CARE DELIVERY WITH AI-DRIVEN NUCLEAR MEDICINE SOFTWARE SOLUTIONS TO PROPEL MARKET      174

11.5         CLINICAL RESEARCH     176

11.5.1      GROWING DEMAND FOR SCALABLE SERVICE SOLUTIONS THAT STREAMLINE IT DEPLOYMENT TO FURTHER MARKET GROWTH          176

12            NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA      179

12.1         INTRODUCTION              180

12.2         ONCOLOGY        180

12.2.1      GROWING NEED FOR CANCER DETECTION AND THERAPY PLANNING THROUGH MOLECULAR IMAGING MODALITIES TO DRIVE GROWTH            180

12.3         NEUROLOGY     182

12.3.1      ADVANTAGES SUCH AS EARLY DETECTION, FUNCTIONAL BRAIN MAPPING, AND AUTOMATED DISEASE TRACKING TO DRIVE DEMAND 182

12.4         CARDIOLOGY    183

12.4.1      NEED TO TRANSFORM CARDIAC NUCLEAR IMAGING WITH SMART TECHNOLOGIES TO BOOST GROWTH       183

12.5         OTHER THERAPEUTIC AREAS    185

13            NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY           187

13.1         INTRODUCTION              188

13.2         UPCOMING TECHNOLOGIES     188

13.2.1      AI & ADVANCED ANALYTICS      190

13.2.1.1  High burden of neurodegenerative diseases and oncology imaging complexity to boost market 190

13.2.2      DOSIMETRY & TREATMENT PLANNING                 191

13.2.2.1  Rise of radioligand therapies like lutetium-177 to increase dosimetry software adoption               191

13.2.3      CLOUD-NATIVE PLATFORMS     192

13.2.3.1  Scalable AI-integrated nuclear medicine solutions with remote accessibility to drive nuclear medicine software growth 192

13.2.4      MOBILE & REMOTE ACCESS        193

13.2.4.1  Growing use of portable imaging devices, hybrid care demands, and supportive reimbursement trends to support market growth 193

13.3         MATURE TECHNOLOGIES            194

13.3.1      IMAGE ACQUISITION & RECONSTRUCTION        195

13.3.1.1  Ability of image reconstruction to drive precision and low-dose imaging in nuclear medicine to boost market  195

13.3.2      PACS INTEGRATION       196

13.3.2.1  Rise of hybrid imaging, need for SUV harmonization, and increasing regulatory focus on dosimetry to propel market           196

13.3.3      QUALITY CONTROL       197

13.3.3.1  Advancing quality control through standardized reconstruction in nuclear medicine to aid growth      197

14            NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER                 199

14.1         INTRODUCTION              200

14.2         HEALTHCARE PROVIDERS           200

14.2.1      HOSPITALS         202

14.2.1.1  Ability of hospitals to drive diagnostic precision and workflow efficiency in nuclear medicine to boost market                202

14.2.2      OUTPATIENT SETTINGS               203

14.2.2.1  Need for accessibility, efficiency, and growth in nuclear medicine software to boost adoption  203

14.2.3      DIAGNOSTIC & IMAGING CENTERS         204

14.2.3.1  Expanding access and precision in nuclear diagnostics to support market growth       204

14.2.4      RADIOPHARMACIES       205

14.2.4.1  Accelerating radiopharmaceutical precision and safety through radiopharmacy software innovations to fuel growth       205

14.2.5      OTHER HEALTHCARE PROVIDERS           206

14.3         PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES                 207

14.3.1      EXPANDING INFLUENCE OF NUCLEAR MEDICINE SOFTWARE IN RADIOPHARMACEUTICAL R&D AND CLINICAL TRIALS TO BOOST MARKET        207

14.4         MEDTECH COMPANIES 209

14.4.1      NEED TO ADVANCE NUCLEAR IMAGING TRIALS WITH PRECISION SOFTWARE INTEGRATION TO PROPEL MARKET                 209

14.5         OTHER END USERS         210

15            NUCLEAR MEDICINE SOFTWARE MARKET, BY REGION                 212

15.1         INTRODUCTION              213

15.2         NORTH AMERICA             213

15.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 214

15.2.2      US           221

15.2.2.1  Emergence of hybrid imaging systems with enhanced diagnostic accuracy to drive market growth        221

15.2.3      CANADA               227

15.2.3.1  Government initiatives and funding to support market growth                 227

15.3         EUROPE               233

15.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      233

15.3.2      GERMANY           240

15.3.2.1  Rising theranostic procedures to drive demand for advanced dosimetry and imaging software         240

15.3.3      UK          246

15.3.3.1  Infrastructure expansion and digital health initiatives to advance market growth       246

15.3.4      FRANCE                252

15.3.4.1  Accelerated digital transformation and expansion of targeted radiotherapy to drive growth               252

15.3.5      ITALY    258

15.3.5.1  Growing need for tailored diagnostics to drive nuclear medicine software market growth       258

15.3.6      SPAIN    264

15.3.6.1  Targeted public investments to drive advancements in nuclear medicine software 264

15.3.7      REST OF EUROPE             270

15.4         ASIA PACIFIC     276

15.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 276

15.4.2      JAPAN   284

15.4.2.1  Deeply ingrained culture of technological advancements in healthcare and medical imaging to support market        284

15.4.3      CHINA  290

15.4.3.1  China’s strategy for healthcare modernization and technological independence to boost growth            290

15.4.4      INDIA    296

15.4.4.1  Steady growth in number of nuclear medicine facilities and SPECT/PET equipment to fuel growth            296

15.4.5      REST OF ASIA PACIFIC   302

15.5         LATIN AMERICA                307

15.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 307

15.5.2      BRAZIL 314

15.5.2.1  Improving healthcare infrastructure to boost procedural volume                 314

15.5.3      MEXICO                320

15.5.3.1  Increasing focus on digital transformation within healthcare system to support market growth       320

15.5.4      REST OF LATIN AMERICA             326

15.6         MIDDLE EAST & AFRICA                331

15.6.1      MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 331

15.6.2      GCC COUNTRIES              338

15.6.2.1  Substantial investments and national visions to transform market                 338

15.6.3      REST OF MIDDLE EAST & AFRICA             344

16            COMPETITIVE LANDSCAPE         350

16.1         OVERVIEW          350

16.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            350

16.2.1      OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEAR MEDICINE SOFTWARE MARKET     351

16.3         REVENUE ANALYSIS, 2020–2024  353

16.4         MARKET SHARE ANALYSIS, 2024                 354

16.4.1      GLOBAL MARKET SHARE ANALYSIS FOR PET

(POSITRON EMISSION TOMOGRAPHY) 357

16.4.2      GLOBAL MARKET SHARE ANALYSIS FOR SPECT

(SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY)                 359

16.5         BRAND/PRODUCT COMPARISON             361

16.6         COMPANY VALUATION & FINANCIAL METRICS 362

16.6.1      FINANCIAL METRICS      362

16.6.2      COMPANY VALUATION 362

16.7         MARKET RANKING ANALYSIS     363

16.8         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 363

16.8.1      STARS   363

16.8.2      EMERGING LEADERS     363

16.8.3      PERVASIVE PLAYERS      364

16.8.4      PARTICIPANTS 364

16.8.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         365

16.8.5.1  Company footprint               365

16.8.5.2  Region footprint   366

16.8.5.3  Software type footprint        367

16.8.5.4  Workflow footprint               368

16.8.5.5  Integration complexity footprint        369

16.8.5.6  Application footprint            370

16.8.5.7  Therapeutic area footprint  371

16.8.5.8  End-user footprint                372

16.9         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        373

16.9.1      PROGRESSIVE COMPANIES         373

16.9.2      RESPONSIVE COMPANIES            373

16.9.3      DYNAMIC COMPANIES  373

16.9.4      STARTING BLOCKS         373

16.9.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 375

16.9.5.1  Detailed list of key startups/SMEs    375

16.9.5.2  Competitive benchmarking of startups/SMEs 375

16.10       COMPETITIVE SCENARIO             377

16.10.1   PRODUCT LAUNCHES & APPROVALS     377

16.10.2   DEALS  378

16.10.3   EXPANSIONS     380

16.10.4   OTHER DEVELOPMENTS              380

17            COMPANY PROFILES      381

17.1         KEY PLAYERS     381

17.1.1      GE HEALTHCARE             381

17.1.1.1  Business overview 381

17.1.1.2  Products & services offered                 382

17.1.1.3  Recent developments           384

17.1.1.3.1                Product launches & approvals            384

17.1.1.3.2                Deals      384

17.1.1.3.3                Expansions             387

17.1.1.4  MnM view              387

17.1.1.4.1                Right to win           387

17.1.1.4.2                Strategic choices   387

17.1.1.4.3                Weaknesses & competitive threats     388

17.1.2      SIEMENS HEALTHINEERS AG      389

17.1.2.1  Business overview 389

17.1.2.2  Products & services offered                 390

17.1.2.3  Recent developments           392

17.1.2.3.1                Product launches  392

17.1.2.3.2                Deals      393

17.1.2.4  MnM view              393

17.1.2.4.1                Right to win           393

17.1.2.4.2                Strategic choices   394

17.1.2.4.3                Weaknesses & competitive threats     394

17.1.3      KONINKLIJKE PHILIPS N.V.          395

17.1.3.1  Business overview 395

17.1.3.2  Products & services offered                 396

17.1.3.3  Recent developments           397

17.1.3.3.1                Product launches  397

17.1.3.4  MnM view              398

17.1.3.4.1                Right to win           398

17.1.3.4.2                Strategic choices   398

17.1.3.4.3                Weaknesses & competitive threats     398

17.1.4      LANTHEUS          399

17.1.4.1  Business overview 399

17.1.4.2  Products & services offered                 400

17.1.4.3  Recent developments           401

17.1.4.3.1                Deals      401

17.1.4.3.2                Other developments             401

17.1.4.4  MnM view              402

17.1.4.4.1                Right to win           402

17.1.4.4.2                Strategic choices   402

17.1.4.4.3                Weaknesses & competitive threats     403

17.1.5      CANON MEDICAL SYSTEMS CORPORATION        404

17.1.5.1  Business overview 404

17.1.5.2  Products & services offered                 405

17.1.5.3  Recent developments           406

17.1.5.3.1                Deals      406

17.1.5.4  MnM view              406

17.1.5.4.1                Right to win           406

17.1.5.4.2                Strategic choices   406

17.1.5.4.3                Weaknesses & competitive threats     407

17.1.6      MIRION TECHNOLOGIES, INC.  408

17.1.6.1  Business overview 408

17.1.6.2  Products & services offered                 409

17.1.6.3  Recent developments           411

17.1.6.3.1                Product launches  411

17.1.6.3.2                Deals      411

17.1.6.4  MnM view              412

17.1.6.4.1                Right to win           412

17.1.6.4.2                Strategic choices   412

17.1.6.4.3                Weaknesses & competitive threats     412

17.1.7      BRAINLAB AG    413

17.1.7.1  Business overview 413

17.1.7.2  Products & services offered                 413

17.1.7.3  Recent developments           414

17.1.7.3.1                Product approvals 414

17.1.8      MIRADA MEDICAL LIMITED        415

17.1.8.1  Business overview 415

17.1.8.2  Products & services offered                 415

17.1.8.3  Recent developments           416

17.1.8.3.1                Product approvals 416

17.1.8.3.2                Deals      416

17.1.9      DOSISOFT SA     418

17.1.9.1  Business overview 418

17.1.9.2  Products & services offered                 418

17.1.9.3  Recent developments           419

17.1.9.3.1                Product approvals 419

17.1.9.3.2                Deals      419

17.1.10   BRACCO GROUP               420

17.1.10.1                 Business overview 420

17.1.10.2                 Products & services offered                 421

17.1.10.3                 Recent developments           421

17.1.10.3.1             Product launches & approvals            421

17.1.11   HERMES MEDICAL SOLUTIONS 422

17.1.11.1                 Business overview 422

17.1.11.2                 Products & services offered                 423

17.1.11.3                 Recent developments           424

17.1.11.3.1             Product launches & approvals            424

17.1.11.3.2             Deals      425

17.1.12   INVIA, LLC           426

17.1.12.1                 Business overview 426

17.1.12.2                 Products & services offered                 426

17.1.12.3                 Recent developments           427

17.1.12.3.1             Product launches  427

17.1.12.3.2             Deals      427

17.1.13   MEDISO LTD.    428

17.1.13.1                 Business overview 428

17.1.13.2                 Products & services offered                 429

17.1.13.3                 Recent developments           430

17.1.13.3.1             Product launches & approvals            430

17.1.14   LABLOGIC SYSTEMS LTD.            431

17.1.14.1                 Business overview 431

17.1.14.2                 Products & services offered                 432

17.1.14.3                 Recent developments           433

17.1.14.3.1             Product approvals 433

17.1.15   COMECER S.P.A. PRIVATE             434

17.1.15.1                 Business overview 434

17.1.15.2                 Products & services offered                 435

17.1.15.3                 Recent developments           436

17.1.15.3.1             Product updates   436

17.1.15.3.2             Deals      436

17.1.16   RAYSEARCH LABORATORIES      437

17.1.16.1                 Business overview 437

17.1.16.2                 Products & services offered                 438

17.1.16.3                 Recent developments           439

17.1.16.3.1             Product launches  439

17.1.17   ULTRASPECT INC.           440

17.1.17.1                 Business overview 440

17.1.17.2                 Products & services offered                 441

17.1.18   SECTRA AB         442

17.1.18.1                 Business overview 442

17.1.18.2                 Products & services offered                 443

17.1.18.3                 Recent developments           444

17.1.18.3.1             Product launches  444

17.1.18.3.2             Deals      444

17.1.19   AGFA-GEVAERT GROUP                445

17.1.19.1                 Business overview 445

17.1.19.2                 Products & services offered                 446

17.1.20   PERCEPTIVE      447

17.1.20.1                 Business overview 447

17.1.20.2                 Products & services offered                 447

17.1.20.3                 Recent developments           448

17.1.20.3.1             Product launches  448

17.1.20.3.2             Deals      448

17.2         OTHER PLAYERS              449

17.2.1      SYNTERMED INC.             449

17.2.2      SEGAMI CORPORATION                450

17.2.3      VERSANT MEDICAL PHYSICS & RADIATION SAFETY                 451

17.2.4      PIXMEO                452

17.2.5      PAIRE    453

17.2.6      SUBTLE MEDICAL, INC. 454

18            APPENDIX           455

18.1         DISCUSSION GUIDE        455

18.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                461

18.3         CUSTOMIZATION OPTIONS        463

18.4         RELATED REPORTS         463

18.5         AUTHOR DETAILS           464

LIST OF TABLES

TABLE 1                INCLUSIONS & EXCLUSIONS       44

TABLE 2                EXCHANGE RATES UTILIZED FOR CONVERSION TO USD                45

TABLE 3                RISK ASSESSMENT: NUCLEAR MEDICINE SOFTWARE MARKET       58

TABLE 4                NUCLEAR MEDICINE SOFTWARE MARKET: IMPACT ANALYSIS           71

TABLE 5                NUCLEAR MEDICINE SOFTWARE MARKET: ROLE IN ECOSYSTEM     81

TABLE 6                NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 86

TABLE 7                EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS           86

TABLE 8                ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 87

TABLE 9                REGULATORY STANDARDS IN NUCLEAR MEDICINE           88

TABLE 10              REGULATORY REQUIREMENTS IN NORTH AMERICA             88

TABLE 11              REGULATORY REQUIREMENTS IN EUROPE                 89

TABLE 12              REGULATORY REQUIREMENTS IN ASIA PACIFIC                 89

TABLE 13              REGULATORY REQUIREMENTS IN LATIN AMERICA             90

TABLE 14              REGULATORY REQUIREMENTS IN MIDDLE EAST & AFRICA 90

TABLE 15              INDICATIVE PRICE FOR NUCLEAR MEDICINE SOFTWARE, BY KEY PLAYER (2024)           92

TABLE 16              AVERAGE SELLING PRICE OF NUCLEAR CARDIOLOGY REPORTING SOFTWARE (2024)     92

TABLE 17              INDICATIVE PRICE FOR NUCLEAR MEDICINE SOFTWARE, BY REGION (2024)   93

TABLE 18              NUCLEAR MEDICINE SOFTWARE MARKET: PORTER’S FIVE FORCES ANALYSIS           94

TABLE 19              JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR NUCLEAR MEDICINE SOFTWARE SOLUTIONS                 96

TABLE 20              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)     98

TABLE 21              KEY BUYING CRITERIA FOR END USERS                 99

TABLE 22              UNMET NEEDS IN NUCLEAR MEDICINE SOFTWARE MARKET       100

TABLE 23              END-USER EXPECTATIONS IN NUCLEAR MEDICINE SOFTWARE MARKET                 101

TABLE 24              US-ADJUSTED RECIPROCAL TARIFF RATES                 113

TABLE 25              NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE,

2023–2030 (USD MILLION)            118

TABLE 26              NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ACQUISITION & RECONSTRUCTION SOFTWARE: MAJOR PLAYERS AND OFFERINGS           120

TABLE 27              NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ACQUISITION & RECONSTRUCTION SOFTWARE, BY REGION, 2023–2030 (USD MILLION)          120

TABLE 28              NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ANALYSIS & QUANTIFICATION SOFTWARE: MAJOR PLAYERS AND OFFERINGS           121

TABLE 29              NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ANALYSIS & QUANTIFICATION SOFTWARE, BY REGION, 2023–2030 (USD MILLION)            122

TABLE 30              NUCLEAR MEDICINE SOFTWARE MARKET FOR WORKFLOW MANAGEMENT & ORCHESTRATION SOFTWARE: MAJOR PLAYERS AND OFFERINGS            123

TABLE 31              NUCLEAR MEDICINE SOFTWARE MARKET FOR WORKFLOW MANAGEMENT & ORCHESTRATION SOFTWARE, BY REGION, 2023–2030 (USD MILLION)   123

TABLE 32              NUCLEAR MEDICINE SOFTWARE MARKET FOR PACS INTEGRATION & DATA MANAGEMENT SOFTWARE: MAJOR PLAYERS AND OFFERINGS            124

TABLE 33              NUCLEAR MEDICINE SOFTWARE MARKET FOR PACS INTEGRATION & DATA MANAGEMENT SOFTWARE, BY REGION, 2023–2030 (USD MILLION)          125

TABLE 34              NUCLEAR MEDICINE SOFTWARE MARKET FOR REPORTING & DOCUMENTATION SOFTWARE: MAJOR PLAYERS AND OFFERINGS              126

TABLE 35              NUCLEAR MEDICINE SOFTWARE MARKET FOR REPORTING & DOCUMENTATION SOFTWARE, BY REGION, 2023–2030 (USD MILLION)            126

TABLE 36              NUCLEAR MEDICINE SOFTWARE MARKET FOR RADIOPHARMACEUTICAL MANAGEMENT SOFTWARE: MAJOR PLAYERS AND OFFERINGS           127

TABLE 37              NUCLEAR MEDICINE SOFTWARE MARKET FOR RADIOPHARMACEUTICAL MANAGEMENT SOFTWARE, BY REGION, 2023–2030 (USD MILLION)          127

TABLE 38              NUCLEAR MEDICINE SOFTWARE MARKET FOR DOSIMETRY & TREATMENT PLANNING SOFTWARE: MAJOR PLAYERS AND OFFERINGS           128

TABLE 39              NUCLEAR MEDICINE SOFTWARE MARKET FOR DOSIMETRY & TREATMENT PLANNING SOFTWARE, BY REGION, 2023–2030 (USD MILLION)            129

TABLE 40              NUCLEAR MEDICINE SOFTWARE MARKET FOR QUALITY CONTROL & ASSURANCE SOFTWARE: MAJOR PLAYERS AND OFFERINGS           130

TABLE 41              NUCLEAR MEDICINE SOFTWARE MARKET FOR QUALITY CONTROL & ASSURANCE SOFTWARE, BY REGION, 2023–2030 (USD MILLION)            130

TABLE 42              NUCLEAR MEDICINE SOFTWARE MARKET FOR AI & ADVANCED ANALYTICS SOFTWARE: MAJOR PLAYERS AND OFFERINGS        131

TABLE 43              NUCLEAR MEDICINE SOFTWARE MARKET FOR AI & ADVANCED ANALYTICS SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 132

TABLE 44              NUCLEAR MEDICINE SOFTWARE MARKET FOR MOBILE & REMOTE ACCESS SOFTWARE: MAJOR PLAYERS AND OFFERINGS        133

TABLE 45              NUCLEAR MEDICINE SOFTWARE MARKET FOR MOBILE & REMOTE ACCESS SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 133

TABLE 46              NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW,

2023–2030 (USD MILLION)            135

TABLE 47              NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ACQUISITION WORKFLOWS: MAJOR PLAYERS AND OFFERINGS        136

TABLE 48              NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ACQUISITION WORKFLOWS, BY REGION, 2023–2030 (USD MILLION)            136

TABLE 49              NUCLEAR MEDICINE SOFTWARE MARKET FOR DATA PROCESSING WORKFLOWS: MAJOR PLAYERS AND OFFERINGS        137

TABLE 50              NUCLEAR MEDICINE SOFTWARE MARKET FOR DATA PROCESSING WORKFLOWS, BY REGION, 2023–2030 (USD MILLION)            138

TABLE 51              NUCLEAR MEDICINE SOFTWARE MARKET FOR REPORTING WORKFLOWS: MAJOR PLAYERS AND OFFERINGS                 139

TABLE 52              NUCLEAR MEDICINE SOFTWARE MARKET FOR REPORTING WORKFLOWS,

BY REGION, 2023–2030 (USD MILLION)   139

TABLE 53              NUCLEAR MEDICINE SOFTWARE MARKET FOR DATA MANAGEMENT WORKFLOWS: MAJOR PLAYERS AND OFFERINGS        140

TABLE 54              NUCLEAR MEDICINE SOFTWARE MARKET FOR DATA MANAGEMENT WORKFLOWS, BY REGION, 2023–2030 (USD MILLION)            141

TABLE 55              NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY,

2023–2030 (USD MILLION)            143

TABLE 56              NUCLEAR MEDICINE SOFTWARE MARKET FOR STANDALONE SOLUTIONS: MAJOR PLAYERS AND OFFERINGS                 144

TABLE 57              NUCLEAR MEDICINE SOFTWARE MARKET FOR STANDALONE SOLUTIONS,

BY REGION, 2023–2030 (USD MILLION)   145

TABLE 58              NUCLEAR MEDICINE SOFTWARE MARKET FOR INTEGRATED SOLUTIONS: MAJOR PLAYERS AND OFFERINGS                 146

TABLE 59              NUCLEAR MEDICINE SOFTWARE MARKET FOR INTEGRATED SOLUTIONS,

BY REGION, 2023–2030 (USD MILLION)   146

TABLE 60              NUCLEAR MEDICINE SOFTWARE MARKET FOR CLOUD-NATIVE PLATFORMS: MAJOR PLAYERS AND OFFERINGS                 147

TABLE 61              NUCLEAR MEDICINE SOFTWARE MARKET FOR CLOUD-NATIVE PLATFORMS,

BY REGION, 2023–2030 (USD MILLION)   148

TABLE 62              NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING,

2023–2030 (USD MILLION)            150

TABLE 63              NUCLEAR MEDICINE SOFTWARE MARKET FOR PERPETUAL/TRADITIONAL LICENSES: MAJOR PLAYERS AND OFFERINGS        151

TABLE 64              NUCLEAR MEDICINE SOFTWARE MARKET FOR PERPETUAL/TRADITIONAL LICENSES, BY REGION, 2023–2030 (USD MILLION) 152

TABLE 65              NUCLEAR MEDICINE SOFTWARE MARKET FOR SUBSCRIPTION/SAAS LICENSES: MAJOR PLAYERS AND OFFERINGS        153

TABLE 66              NUCLEAR MEDICINE SOFTWARE MARKET FOR SUBSCRIPTION/SAAS LICENSES,

BY REGION, 2023–2030 (USD MILLION)   153

TABLE 67              NUCLEAR MEDICINE SOFTWARE MARKET FOR USAGE-BASED LICENSES: MAJOR PLAYERS AND OFFERINGS                 154

TABLE 68              NUCLEAR MEDICINE SOFTWARE MARKET FOR USAGE-BASED LICENSES,

BY REGION, 2023–2030 (USD MILLION)   155

TABLE 69              NUCLEAR MEDICINE SOFTWARE MARKET FOR ENTERPRISE AGREEMENTS: MAJOR PLAYERS AND OFFERINGS                 156

TABLE 70              NUCLEAR MEDICINE SOFTWARE MARKET FOR ENTERPRISE AGREEMENTS,

BY REGION, 2023–2030 (USD MILLION)   156

TABLE 71              NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL,

2023–2030 (USD MILLION)            158

TABLE 72              NUCLEAR MEDICINE SOFTWARE MARKET FOR SOFTWARE LICENSES: MAJOR PLAYERS AND OFFERINGS                 159

TABLE 73              NUCLEAR MEDICINE SOFTWARE MARKET FOR SOFTWARE LICENSES, BY REGION, 2023–2030 (USD MILLION)                 159

TABLE 74              NUCLEAR MEDICINE SOFTWARE MARKET FOR MAINTENANCE & SUPPORT SERVICES: MAJOR PLAYERS AND OFFERINGS        160

TABLE 75              NUCLEAR MEDICINE SOFTWARE MARKET FOR MAINTENANCE & SUPPORT,

BY REGION, 2023–2030 (USD MILLION)   161

TABLE 76              NUCLEAR MEDICINE SOFTWARE MARKET FOR PROFESSIONAL SERVICES: MAJOR PLAYERS AND OFFERINGS                 162

TABLE 77              NUCLEAR MEDICINE SOFTWARE MARKET FOR PROFESSIONAL SERVICES,

BY REGION, 2023–2030 (USD MILLION)   163

TABLE 78              NUCLEAR MEDICINE SOFTWARE MARKET FOR CLOUD SERVICES: MAJOR PLAYERS AND OFFERINGS     164

TABLE 79              NUCLEAR MEDICINE SOFTWARE MARKET FOR CLOUD SERVICES, BY REGION, 2023–2030 (USD MILLION)                 164

TABLE 80              NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            166

TABLE 81              NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS: MAJOR PLAYERS AND OFFERINGS                 167

TABLE 82              NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         167

TABLE 83              NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS,

BY REGION, 2023–2030 (USD MILLION)   167

TABLE 84              NUCLEAR MEDICINE SOFTWARE MARKET FOR AUTOMATED IMAGE INTERPRETATION, BY REGION, 2023–2030 (USD MILLION) 168

TABLE 85              NUCLEAR MEDICINE SOFTWARE MARKET FOR TUMOR SEGMENTATION & QUANTIFICATION, BY REGION, 2023–2030 (USD MILLION)            169

TABLE 86              NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS: MAJOR PLAYERS AND OFFERINGS        170

TABLE 87              NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         171

TABLE 88              NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS,

BY REGION, 2023–2030 (USD MILLION)   171

TABLE 89              NUCLEAR MEDICINE SOFTWARE MARKET FOR PREDICTIVE ANALYTICS, BY REGION, 2023–2030 (USD MILLION)                 172

TABLE 90              NUCLEAR MEDICINE SOFTWARE MARKET FOR WORKFLOW OPTIMIZATION & QUALITY CONTROL, BY REGION, 2023–2030 (USD MILLION)            173

TABLE 91              NUCLEAR MEDICINE SOFTWARE MARKET FOR PERSONALIZED DOSIMETRY CALCULATIONS, BY REGION, 2023–2030 (USD MILLION)       173

TABLE 92              NUCLEAR MEDICINE SOFTWARE MARKET FOR THERANOSTICS, BY REGION,

2023–2030 (USD MILLION)            174

TABLE 93              NUCLEAR MEDICINE SOFTWARE MARKET FOR EMERGENCY STAT WORKFLOWS: MAJOR PLAYERS AND OFFERINGS        176

TABLE 94              NUCLEAR MEDICINE SOFTWARE MARKET FOR EMERGENCY STAT WORKFLOWS,

BY REGION, 2023–2030 (USD MILLION)   176

TABLE 95              NUCLEAR MEDICINE SOFTWARE MARKET FOR CLINICAL RESEARCH APPLICATIONS: MAJOR PLAYERS AND OFFERINGS        178

TABLE 96              NUCLEAR MEDICINE SOFTWARE MARKET FOR CLINICAL RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 178

TABLE 97              NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            180

TABLE 98              NUCLEAR MEDICINE SOFTWARE MARKET FOR ONCOLOGY: MAJOR PLAYERS AND OFFERINGS 181

TABLE 99              NUCLEAR MEDICINE SOFTWARE MARKET FOR ONCOLOGY, BY REGION,

2023–2030 (USD MILLION)            181

TABLE 100            NUCLEAR MEDICINE SOFTWARE MARKET FOR NEUROLOGY: MAJOR PLAYERS AND OFFERINGS               182

TABLE 101            NUCLEAR MEDICINE SOFTWARE MARKET FOR NEUROLOGY, BY REGION,

2023–2030 (USD MILLION)            183

TABLE 102            NUCLEAR MEDICINE SOFTWARE MARKET FOR CARDIOLOGY: MAJOR PLAYERS AND OFFERINGS             184

TABLE 103            NUCLEAR MEDICINE SOFTWARE MARKET FOR CARDIOLOGY, BY REGION,

2023–2030 (USD MILLION)            184

TABLE 104            NUCLEAR MEDICINE SOFTWARE MARKET FOR OTHER THERAPEUTIC AREAS: MAJOR PLAYERS AND OFFERINGS        185

TABLE 105            NUCLEAR MEDICINE SOFTWARE MARKET FOR OTHER THERAPEUTIC AREAS,

BY REGION, 2023–2030 (USD MILLION)   186

TABLE 106            NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY,

2023–2030 (USD MILLION)            188

TABLE 107            NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES: MAJOR PLAYERS AND OFFERINGS                 189

TABLE 108            NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES,

BY TYPE, 2023–2030 (USD MILLION)         189

TABLE 109            NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES,

BY REGION, 2023–2030 (USD MILLION)   190

TABLE 110            NUCLEAR MEDICINE SOFTWARE MARKET FOR AI & ADVANCED ANALYTICS,

BY REGION, 2023–2030 (USD MILLION)   191

TABLE 111            NUCLEAR MEDICINE SOFTWARE MARKET FOR DOSIMETRY & TREATMENT PLANNING, BY REGION, 2023–2030 (USD MILLION) 192

TABLE 112            NUCLEAR MEDICINE SOFTWARE MARKET FOR CLOUD-NATIVE PLATFORMS TECHNOLOGY, BY REGION, 2023–2030 (USD MILLION)       193

TABLE 113            NUCLEAR MEDICINE SOFTWARE MARKET FOR MOBILE & REMOTE ACCESS,

BY REGION, 2023–2030 (USD MILLION)   194

TABLE 114            NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)                 195

TABLE 115            NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES,

BY REGION, 2023–2030 (USD MILLION)   195

TABLE 116            NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ACQUISITION & RECONSTRUCTION, BY REGION, 2023–2030 (USD MILLION)       196

TABLE 117            NUCLEAR MEDICINE SOFTWARE MARKET FOR PACS INTEGRATION, BY REGION, 2023–2030 (USD MILLION)                 197

TABLE 118            NUCLEAR MEDICINE SOFTWARE MARKET FOR QUALITY CONTROL, BY REGION, 2023–2030 (USD MILLION)                 198

TABLE 119            NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            200

TABLE 120            NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS: MAJOR PLAYERS AND OFFERINGS                 201

TABLE 121            NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)                 201

TABLE 122            NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS,

BY REGION, 2023–2030 (USD MILLION)   202

TABLE 123            NUCLEAR MEDICINE SOFTWARE MARKET FOR HOSPITALS, BY REGION,

2023–2030 (USD MILLION)            203

TABLE 124            NUCLEAR MDICINE SOFTWARE MARKET FOR OUTPATIENT SETTINGS, BY REGION, 2023–2030 (USD MILLION)                 204

TABLE 125            NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC & IMAGING CENTERS, BY REGION, 2023–2030 (USD MILLION)            204

TABLE 126            NUCLEAR MDICINE SOFTWARE MARKET FOR RADIOPHARMACIES, BY REGION, 2023–2030 (USD MILLION)                 205

TABLE 127            NUCLEAR MEDICINE SOFTWARE MARKET FOR OTHER HEALTHCARE ROVIDERS,

BY REGION, 2023–2030 (USD MILLION)   206

TABLE 128            NUCLEAR MEDICINE SOFTWARE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: MAJOR PLAYERS AND OFFERINGS           208

TABLE 129            NUCLEAR MEDICINE SOFTWARE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)          208

TABLE 130            NUCLEAR MEDICINE SOFTWARE MARKET FOR MEDTECH COMPANIES: MAJOR PLAYERS AND OFFERINGS                 209

TABLE 131            NUCLEAR MEDICINE SOFTWARE MARKET FOR MEDTECH COMPANIES, BY REGION, 2023–2030 (USD MILLION)                 210

TABLE 132            NUCLEAR MEDICINE SOFTWARE MARKET FOR OTHER END USERS: MAJOR PLAYERS AND OFFERINGS  211

TABLE 133            NUCLEAR MEDICINE SOFTWARE MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)                 211

TABLE 134            NUCLEAR MEDICINE SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION)          213

TABLE 135            NORTH AMERICA: MACROECONOMIC OUTLOOK           215

TABLE 136            NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            216

TABLE 137            NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)            216

TABLE 138            NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)                 217

TABLE 139            NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 217

TABLE 140            NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)            217

TABLE 141            NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)            218

TABLE 142            NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            218

TABLE 143            NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                218

TABLE 144            NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                219

TABLE 145            NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            219

TABLE 146            NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 219

TABLE 147            NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)            220

TABLE 148            NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)            220

TABLE 149            NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            220

TABLE 150            NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)            221

TABLE 151            US: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE,

2023–2030 (USD MILLION)            222

TABLE 152            US: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW,

2023–2030 (USD MILLION)            222

TABLE 153            US: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)                 223

TABLE 154            US: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING,

2023–2030 (USD MILLION)            223

TABLE 155            US: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL,

2023–2030 (USD MILLION)            223

TABLE 156            US: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            224

TABLE 157            US: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            224

TABLE 158            US: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            224

TABLE 159            US: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            225

TABLE 160            US: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY,

2023–2030 (USD MILLION)            225

TABLE 161            US: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES,

BY TYPE, 2023–2030 (USD MILLION)         225

TABLE 162            US: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES,

BY TYPE, 2023–2030 (USD MILLION)         226

TABLE 163            US: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            226

TABLE 164            US: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE, 2023–2030 (USD MILLION)         226

TABLE 165            CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE,

2023–2030 (USD MILLION)            228

TABLE 166            CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW,

2023–2030 (USD MILLION)            228

TABLE 167            CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)            229

TABLE 168            CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)                 229

TABLE 169            CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL,

2023–2030 (USD MILLION)            229

TABLE 170            CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            230

TABLE 171            CANADA: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 230

TABLE 172            CANADA: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)       230

TABLE 173            CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            231

TABLE 174            CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)            231

TABLE 175            CANADA: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 231

TABLE 176            CANADA: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 232

TABLE 177            CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            232

TABLE 178            CANADA: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 232

TABLE 179            EUROPE: MACROECONOMIC OUTLOOK                 234

TABLE 180            EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            234

TABLE 181            EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE,

2023–2030 (USD MILLION)            235

TABLE 182            EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW,

2023–2030 (USD MILLION)            235

TABLE 183            EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)            236

TABLE 184            EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)                 236

TABLE 185            EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL,

2023–2030 (USD MILLION)            236

TABLE 186            EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            237

TABLE 187            EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 237

TABLE 188            EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)       237

TABLE 189            EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            238

TABLE 190            EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)            238

TABLE 191            EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 238

TABLE 192            EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 239

TABLE 193            EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            239

TABLE 194            EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 239

TABLE 195            GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE,

2023–2030 (USD MILLION)            241

TABLE 196            GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW,

2023–2030 (USD MILLION)            241

TABLE 197            GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)            242

TABLE 198            GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)                 242

TABLE 199            GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL,

2023–2030 (USD MILLION)            242

TABLE 200            GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            243

TABLE 201            GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 243

TABLE 202            GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)       243

TABLE 203            GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                 244

TABLE 204            GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)            244

TABLE 205            GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 244

TABLE 206            GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 245

TABLE 207            GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            245

TABLE 208            GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 245

TABLE 209            UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE,

2023–2030 (USD MILLION)            247

TABLE 210            UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW,

2023–2030 (USD MILLION)            247

TABLE 211            UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)                 248

TABLE 212            UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING,

2023–2030 (USD MILLION)            248

TABLE 213            UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL,

2023–2030 (USD MILLION)            248

TABLE 214            UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            249

TABLE 215            UK: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         249

TABLE 216            UK: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            249

TABLE 217            UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            250

TABLE 218            UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY,

2023–2030 (USD MILLION)            250

TABLE 219            UK: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES,

BY TYPE, 2023–2030 (USD MILLION)         250

TABLE 220            UK: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES,

BY TYPE, 2023–2030 (USD MILLION)         251

TABLE 221            UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            251

TABLE 222            UK: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE, 2023–2030 (USD MILLION)         251

TABLE 223            FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE,

2023–2030 (USD MILLION)            253

TABLE 224            FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW,

2023–2030 (USD MILLION)            253

TABLE 225            FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)            254

TABLE 226            FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)                 254

TABLE 227            FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL,

2023–2030 (USD MILLION)            254

TABLE 228            FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            255

TABLE 229            FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 255

TABLE 230            FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)       255

TABLE 231            FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            256

TABLE 232            FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)            256

TABLE 233            FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 256

TABLE 234            FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 257

TABLE 235            FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            257

TABLE 236            FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 257

TABLE 237            ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE,

2023–2030 (USD MILLION)            259

TABLE 238            ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW,

2023–2030 (USD MILLION)            259

TABLE 239            ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)            260

TABLE 240            ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)                 260

TABLE 241            ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL,

2023–2030 (USD MILLION)            260

TABLE 242            ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            261

TABLE 243            ITALY: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 261

TABLE 244            ITALY: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)       261

TABLE 245            ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            262

TABLE 246            ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)            262

TABLE 247            ITALY: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 262

TABLE 248            ITALY: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES,

BY TYPE, 2023–2030 (USD MILLION)         263

TABLE 249            ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            263

TABLE 250            ITALY: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE, 2023–2030 (USD MILLION)         263

TABLE 251            SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE,

2023–2030 (USD MILLION)            265

TABLE 252            SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW,

2023–2030 (USD MILLION)            265

TABLE 253            SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)            266

TABLE 254            SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)                 266

TABLE 255            SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL,

2023–2030 (USD MILLION)            266

TABLE 256            SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            267

TABLE 257            SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 267

TABLE 258            SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)       267

TABLE 259            SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            268

TABLE 260            SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)            268

TABLE 261            SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 268

TABLE 262            SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES,

BY TYPE, 2023–2030 (USD MILLION)         269

TABLE 263            SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            269

TABLE 264            SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 269

TABLE 265            REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)            271

TABLE 266            REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)                 271

TABLE 267            REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 272

TABLE 268            REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)            272

TABLE 269            REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)            272

TABLE 270            REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            273

TABLE 271            REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                273

TABLE 272            REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                273

TABLE 273            REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            274

TABLE 274            REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 274

TABLE 275            REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)            274

TABLE 276            REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)            275

TABLE 277            REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            275

TABLE 278            REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)            275

TABLE 279            ASIA PACIFIC: MACROECONOMIC OUTLOOK                 277

TABLE 280            ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            279

TABLE 281            ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)                 279

TABLE 282            ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW,

2023–2030 (USD MILLION)            280

TABLE 283            ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)            280

TABLE 284            ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)                 280

TABLE 285            ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)                 281

TABLE 286            ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            281

TABLE 287            ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 281

TABLE 288            ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)       282

TABLE 289            ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                 282

TABLE 290            ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)            282

TABLE 291            ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 283

TABLE 292            ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 283

TABLE 293            ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            283

TABLE 294            ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 284

TABLE 295            JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE,

2023–2030 (USD MILLION)            285

TABLE 296            JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW,

2023–2030 (USD MILLION)            285

TABLE 297            JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)            286

TABLE 298            JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)                 286

TABLE 299            JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL,

2023–2030 (USD MILLION)            286

TABLE 300            JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            287

TABLE 301            JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 287

TABLE 302            JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)       287

TABLE 303            JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            288

TABLE 304            JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)            288

TABLE 305            JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 288

TABLE 306            JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES,

BY TYPE, 2023–2030 (USD MILLION)         289

TABLE 307            JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            289

TABLE 308            JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 289

TABLE 309            CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE,

2023–2030 (USD MILLION)            291

TABLE 310            CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW,

2023–2030 (USD MILLION)            291

TABLE 311            CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)            292

TABLE 312            CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)                 292

TABLE 313            CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL,

2023–2030 (USD MILLION)            292

TABLE 314            CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            293

TABLE 315            CHINA: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 293

TABLE 316            CHINA: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)       293

TABLE 317            CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            294

TABLE 318            CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)            294

TABLE 319            CHINA: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 294

TABLE 320            CHINA: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES,

BY TYPE, 2023–2030 (USD MILLION)         295

TABLE 321            CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            295

TABLE 322            CHINA: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 295

TABLE 323            INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE,

2023–2030 (USD MILLION)            297

TABLE 324            INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW,

2023–2030 (USD MILLION)            297

TABLE 325            INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)            298

TABLE 326            INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)                 298

TABLE 327            INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL,

2023–2030 (USD MILLION)            298

TABLE 328            INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            299

TABLE 329            INDIA: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 299

TABLE 330            INDIA: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)       299

TABLE 331            INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            300

TABLE 332            INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)            300

TABLE 333            INDIA: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 300

TABLE 334            INDIA: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES,

BY TYPE, 2023–2030 (USD MILLION)         301

TABLE 335            INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            301

TABLE 336            INDIA: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE, 2023–2030 (USD MILLION)         301

TABLE 337            REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)            302

TABLE 338            REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)                 303

TABLE 339            REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 303

TABLE 340            REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)            303

TABLE 341            REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)            304

TABLE 342            REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            304

TABLE 343            REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                304

TABLE 344            REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                305

TABLE 345            REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            305

TABLE 346            REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 305

TABLE 347            REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)            306

TABLE 348            REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)            306

TABLE 349            REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)                 306

TABLE 350            REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)            307

TABLE 351            LATIN AMERICA: MACROECONOMIC OUTLOOK                 308

TABLE 352            LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            308

TABLE 353            LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)            309

TABLE 354            LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW,

2023–2030 (USD MILLION)            309

TABLE 355            LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 310

TABLE 356            LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)            310

TABLE 357            LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)            310

TABLE 358            LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            311

TABLE 359            LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                311

TABLE 360            LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                311

TABLE 361            LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            312

TABLE 362            LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 312

TABLE 363            LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)            312

TABLE 364            LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)            313

TABLE 365            LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            313

TABLE 366            LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)            313

TABLE 367            BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE,

2023–2030 (USD MILLION)            315

TABLE 368            BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW,

2023–2030 (USD MILLION)            315

TABLE 369            BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)            316

TABLE 370            BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)                 316

TABLE 371            BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL,

2023–2030 (USD MILLION)            316

TABLE 372            BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            317

TABLE 373            BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 317

TABLE 374            BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)       317

TABLE 375            BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            318

TABLE 376            BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)            318

TABLE 377            BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 318

TABLE 378            BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 319

TABLE 379            BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            319

TABLE 380            BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 319

TABLE 381            MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE,

2023–2030 (USD MILLION)            321

TABLE 382            MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW,

2023–2030 (USD MILLION)            321

TABLE 383            MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)            322

TABLE 384            MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)                 322

TABLE 385            MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL,

2023–2030 (USD MILLION)            322

TABLE 386            MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            323

TABLE 387            MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 323

TABLE 388            MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)       323

TABLE 389            MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            324

TABLE 390            MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)            324

TABLE 391            MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 324

TABLE 392            MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 325

TABLE 393            MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            325

TABLE 394            MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 325

TABLE 395            REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)            326

TABLE 396            REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET,

BY WORKFLOW, 2023–2030 (USD MILLION)           327

TABLE 397            REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET,

BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)                 327

TABLE 398            REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)            327

TABLE 399            REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)            328

TABLE 400            REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       328

TABLE 401            REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                328

TABLE 402            REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                329

TABLE 403            REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET,

BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)          329

TABLE 404            REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET,

BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)                 329

TABLE 405            REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)            330

TABLE 406            REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)            330

TABLE 407            REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)                 330

TABLE 408            REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)            331

TABLE 409            MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK           332

TABLE 410            MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION)                 332

TABLE 411            MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)            333

TABLE 412            MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET,

BY WORKFLOW, 2023–2030 (USD MILLION)           333

TABLE 413            MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET,

BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)                 334

TABLE 414            MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)            334

TABLE 415            MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)            334

TABLE 416            MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       335

TABLE 417            MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                335

TABLE 418            MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                335

TABLE 419            MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET,

BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)          336

TABLE 420            MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET,

BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)                 336

TABLE 421            MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)            336

TABLE 422            MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)            337

TABLE 423            MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)                 337

TABLE 424            MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)            337

TABLE 425            GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)            339

TABLE 426            GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)                 339

TABLE 427            GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 340

TABLE 428            GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)            340

TABLE 429            GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)            340

TABLE 430            GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            341

TABLE 431            GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                341

TABLE 432            GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                341

TABLE 433            GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            342

TABLE 434            GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 342

TABLE 435            GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)            342

TABLE 436            GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)            343

TABLE 437            GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            343

TABLE 438            GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)            343

TABLE 439            REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET,

BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 345

TABLE 440            REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET,

BY WORKFLOW, 2023–2030 (USD MILLION)           345

TABLE 441            REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET,

BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)                 346

TABLE 442            REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET,

BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)     346

TABLE 443            REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET,

BY REVENUE MODEL, 2023–2030 (USD MILLION)                346

TABLE 444            REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       347

TABLE 445            REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)        347

TABLE 446            REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)        347

TABLE 447            REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET,

BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)          348

TABLE 448            REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET,

BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)                 348

TABLE 449            REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)     348

TABLE 450            REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)         349

TABLE 451            REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET,

BY END USER, 2023–2030 (USD MILLION)               349

TABLE 452            REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)         349

TABLE 453            OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NULEAR MEDICINE SOFTWARE MARKET, JANUARY 2022–JUNE 2025  351

TABLE 454            NUCLEAR MEDICINE SOFTWARE MARKET: DEGREE OF COMPETITION         355

TABLE 455            PET SOFTWARE MARKET: DEGREE OF COMPETITION 358

TABLE 456            SPECT SOFTWARE MARKET: DEGREE OF COMPETITION 360

TABLE 457            NUCLEAR MEDICINE SOFTWARE MARKET: REGION FOOTPRINT     366

TABLE 458            NUCLEAR MEDICINE SOFTWARE MARKET: SOFTWARE TYPE FOOTPRINT   367

TABLE 459            NUCLEAR MEDICINE SOFTWARE MARKET: WORKFLOW FOOTPRINT             368

TABLE 460            NUCLEAR MEDICINE SOFTWARE MARKET: INTEGRATION COMPLEXITY FOOTPRINT            369

TABLE 461            NUCLEAR MEDICINE SOFTWARE MARKET: APPLICATION FOOTPRINT         370

TABLE 462            NUCLEAR MEDICINE SOFTWARE MARKET: THERAPEUTIC AREA FOOTPRINT            371

TABLE 463            NUCLEAR MEDICINE SOFTWARE MARKET: END-USER FOOTPRINT            372

TABLE 464            NUCLEAR MEDICINE SOFTWARE MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS               375

TABLE 465            NUCLEAR MEDICINE SOFTWARE MARKET: COMPETITIVE BENCHMARKING OF SMES/STARTUPS, BY REGION                375

TABLE 466            NUCLEAR MEDICINE SOFTWARE MARKET: COMPETITIVE BENCHMARKING OF SMES/STARTUPS, BY SOFTWARE TYPE              376

TABLE 467            NUCLEAR MEDICINE SOFTWARE MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–MAY 2025                 377

TABLE 468            NUCLEAR MEDICINE SOFTWARE MARKET: DEALS, JANUARY 2022–MAY 2025                378

TABLE 469            NUCLEAR MEDICINE SOFTWARE MARKET: EXPANSIONS,

JANUARY 2022–MAY 2025               380

TABLE 470            NUCLEAR MEDICINE SOFTWARE MARKET: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025          380

TABLE 471            GE HEALTHCARE: COMPANY OVERVIEW                 381

TABLE 472            GE HEALTHCARE: PRODUCTS & SERVICES OFFERED             382

TABLE 473            GE HEALTHCARE: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2022–MAY 2025 CHECK                384

TABLE 474            GE HEALTHCARE: DEALS, JANUARY 2022–MAY 2025        384

TABLE 475            GE HEALTHCARE: EXPANSIONS, JANUARY 2022–MAY 2025              387

TABLE 476            SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW          389

TABLE 477            SIEMENS HEALTHINEERS AG: PRODUCTS & SERVICES OFFERED        390

TABLE 478            SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025      392

TABLE 479            SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022–MAY 2025   393

TABLE 480            KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW          395

TABLE 481            KONINKLIJKE PHILIPS N.V.: PRODUCTS & SERVICES OFFERED        396

TABLE 482            KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025      397

TABLE 483            LANTHEUS: COMPANY OVERVIEW          399

TABLE 484            LANTHEUS: PRODUCTS & SERVICES OFFERED                 400

TABLE 485            LANTHEUS: DEALS, JANUARY 2022–MAY 2025                 401

TABLE 486            LANTHEUS: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025   401

TABLE 487            CANON MEDICAL SYSTEMS CORPORATION: COMPANY OVERVIEW   404

TABLE 488            CANON MEDICAL SYSTEMS CORPORATION: PRODUCTS & SERVICES OFFERED            405

TABLE 489            CANON MEDICAL SYSTEMS CORPORATION: DEALS, JANUARY 2022–MAY 2025                406

TABLE 490            MIRION TECHNOLOGIES, INC.: COMPANY OVERVIEW          408

TABLE 491            MIRION TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED        409

TABLE 492            MIRION TECHNOLOGIES, INC.: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025      411

TABLE 493            MIRION TECHNOLOGIES, INC.: DEALS, JANUARY 2022–MAY 2025               411

TABLE 494            BRAINLAB AG: COMPANY OVERVIEW     413

TABLE 495            BRAINLAB AG: PRODUCTS & SERVICES OFFERED             413

TABLE 496            BRAINLAB AG: PRODUCT APPROVALS, JANUARY 2022–MAY 2025               414

TABLE 497            MIRADA MEDICAL LIMITED: COMPANY OVERVIEW          415

TABLE 498            MIRADA MEDICAL LIMITED: PRODUCTS & SERVICES OFFERED        415

TABLE 499            MIRADA MEDICAL LIMITED: PRODUCT APPROVALS, JANUARY 2022–MAY 2025    416

TABLE 500            MIRADA MEDICAL LIMITED: DEALS, JANUARY 2022–MAY 2025   416

TABLE 501            DOSISOFT SA: COMPANY OVERVIEW     418

TABLE 502            DOSISOFT SA: PRODUCTS & SERVICES OFFERED                 418

TABLE 503            DOSISOFT SA: PRODUCT APPROVALS, JANUARY 2022–MAY 2025   419

TABLE 504            DOSISOFT SA: DEALS, JANUARY 2022–MAY 2025                 419

TABLE 505            BRACCO GROUP: COMPANY OVERVIEW                 420

TABLE 506            BRACCO GROUP: PRODUCTS & SERVICES OFFERED             421

TABLE 507            BRACCO GROUP: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–MAY 2025    421

TABLE 508            HERMES MEDICAL SOLUTIONS: COMPANY OVERVIEW          422

TABLE 509            HERMES MEDICAL SOLUTIONS: PRODUCTS & SERVICES OFFERED        423

TABLE 510            HERMES MEDICAL SOLUTIONS: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2022–MAY 2025               424

TABLE 511            HERMES MEDICAL SOLUTIONS: DEALS, JANUARY 2022–MAY 2025               425

TABLE 512            INVIA, LLC: COMPANY OVERVIEW           426

TABLE 513            INVIA, LLC: PRODUCTS & SERVICES OFFERED                 426

TABLE 514            INVIA, LLC: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025   427

TABLE 515            INVIA, LLC: DEALS, JANUARY 2022–MAY 2025                 427

TABLE 516            MEDISO LTD.: COMPANY OVERVIEW     428

TABLE 517            MEDISO LTD.: PRODUCTS & SERVICES OFFERED                 429

TABLE 518            MEDISO LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–MAY 2025    430

TABLE 519            LABLOGIC SYSTEMS LTD.: COMPANY OVERVIEW          431

TABLE 520            LABLOGIC SYSTEMS LTD.: PRODUCTS & SERVICES OFFERED        432

TABLE 521            LABLOGIC SYSTEMS LTD.: PRODUCT APPROVALS, JANUARY 2022–MAY 2025    433

TABLE 522            COMECER S.P.A.: COMPANY OVERVIEW                 434

TABLE 523            COMECER S.P.A.: PRODUCTS & SERVICES OFFERED             435

TABLE 524            COMECER S.P.A.: PRODUCT UPDTAES, JANUARY 2022–MAY 2025   436

TABLE 525            COMECER S.P.A.: DEALS, JANUARY 2022–MAY 2025        436

TABLE 526            RAYSEARCH LABORATORIES: COMPANY OVERVIEW          437

TABLE 527            RAYSEARCH LABORATORIES: PRODUCTS & SERVICES OFFERED        438

TABLE 528            RAYSEARCH LABORATORIES: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025      439

TABLE 529            ULTRASPECT INC.: COMPANY OVERVIEW                 440

TABLE 530            ULTRASPECT INC.: PRODUCTS & SERVICES OFFERED             441

TABLE 531            SECTRA AB: COMPANY OVERVIEW          442

TABLE 532            SECTRA AB: PRODUCTS & SERVICES OFFERED                 443

TABLE 533            SECTRA AB: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025   444

TABLE 534            SECTRA AB: DEALS, JANUARY 2022–MAY 2025                 444

TABLE 535            AGFA-GEVAERT GROUP: COMPANY OVERVIEW                 445

TABLE 536            AGFA-GEVAERT GROUP: PRODUCTS & SERVICES OFFERED        446

TABLE 537            PERCEPTIVE: COMPANY OVERVIEW       447

TABLE 538            PERCEPTIVE: PRODUCTS & SERVICES OFFERED                 447

TABLE 539            PERCEPTIVE: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025   448

TABLE 540            PERCEPTIVE: DEALS, JANUARY 2022–MAY 2025                 448

LIST OF FIGURES

FIGURE 1              NUCLEAR MEDICINE SOFTWARE MARKET SEGMENTATION & REGIONAL SCOPE    43

FIGURE 2              RESEARCH DESIGN         47

FIGURE 3              BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION  50

FIGURE 4              RESEARCH METHODOLOGY: HYPOTHESIS BUILDING           52

FIGURE 5              BOTTOM-UP APPROACH              53

FIGURE 6              TOP-DOWN APPROACH                54

FIGURE 7              CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NUCLEAR MEDICINE SOFTWARE INDUSTRY                 55

FIGURE 8              CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS                 55

FIGURE 9              DATA TRIANGULATION METHODOLOGY                 57

FIGURE 10            NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE,

2025 VS. 2030 (USD MILLION)      59

FIGURE 11            NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW,

2025 VS. 2030 (USD MILLION)      60

FIGURE 12            NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY,

2025 VS. 2030 (USD MILLION)      60

FIGURE 13            NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING,

2025 VS. 2030 (USD MILLION)      61

FIGURE 14            NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL,

2025 VS. 2030 (USD MILLION)      61

FIGURE 15            NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION,

2025 VS. 2030 (USD MILLION)      62

FIGURE 16            NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA,

2025 VS. 2030 (USD MILLION)      62

FIGURE 17            NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY,

2025 VS. 2030 (USD MILLION)      63

FIGURE 18            NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER,

2025 VS. 2030 (USD MILLION)      63

FIGURE 19            NUCLEAR MEDICINE SOFTWARE MARKET: REGIONAL SNAPSHOT  64

FIGURE 20            GROWING ADOPTION OF ADVANCED IMAGING MODALITIES, ENHANCED INTEROPERABILITY, AND EXPANSION OF REMOTE ACCESS TO DRIVE MARKET GROWTH                 66

FIGURE 21            INTEGRATED SOLUTIONS SEGMENT AND JAPAN TO COMMAND LARGEST SHARES OF ASIA PACIFIC MARKET IN 2024                67

FIGURE 22            MARKET IN CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD          68

FIGURE 23            ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD       68

FIGURE 24            EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD    69

FIGURE 25            MARKET DYNAMICS: NUCLEAR MEDICINE SOFTWARE MARKET       70

FIGURE 26            TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES           77

FIGURE 27            NUCLEAR MEDICINE SOFTWARE MARKET: ECOSYSTEM ANALYSIS  80

FIGURE 28            NUCLEAR MEDICINE SOFTWARE MARKET: SUPPLY CHAIN ANALYSIS             83

FIGURE 29            NUCLEAR MEDICINE SOFTWARE: PORTER’S FIVE FORCES ANALYSIS 94

FIGURE 30            JURISDICTION AND TOP APPLICANT ANALYSIS OF NUCLEAR MEDICINE

SOFTWARE SOLUTIONS                96

FIGURE 31            TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR NUCLEAR MEDICINE SOFTWARE MARKET (JANUARY 2015 TO MAY 2025)          97

FIGURE 32            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS              98

FIGURE 33            KEY BUYING CRITERIA FOR END USERS                 99

FIGURE 34            INVESTOR DEALS AND FUNDING IN NUCLEAR MEDICINE SOFTWARE MARKET                 105

FIGURE 35            MARKET POTENTIAL OF AI/GENERATIVE AI ON NUCLEAR MEDICINE SOFTWARE SOLUTIONS ACROSS INDUSTRIES       107

FIGURE 36            PRICE IMPACT ANALYSIS             115

FIGURE 37            NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET SNAPSHOT               215

FIGURE 38            ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET SNAPSHOT       278

FIGURE 39            REVENUE ANALYSIS OF KEY PLAYERS IN NUCLEAR MEDICINE SOFTWARE MARKET, 2020–2024      354

FIGURE 40            MARKET SHARE ANALYSIS OF KEY PLAYERS IN NUCLEAR MEDICINE SOFTWARE MARKET, 2024                 355

FIGURE 41            MARKET SHARE ANALYSIS OF KEY PLAYERS IN PET SOFTWARE MARKET, 2024   357

FIGURE 42            MARKET SHARE ANALYSIS OF KEY PLAYERS IN SPECT SOFTWARE MARKET, 2024              359

FIGURE 43            NUCLEAR MEDICINE SOFTWARE MARKET: BRAND/SOFTWARE

COMPARITIVE ANALYSIS              361

FIGURE 44            EV/EBITDA OF KEY VENDORS   362

FIGURE 45            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA            362

FIGURE 46            NUCLEAR MEDICINE SOFTWARE MARKET: KEY PLAYERS, 2024   363

FIGURE 47            NUCLEAR MEDICINE SOFTWARE MARKET: COMPANY EVALUATION

MATRIX (KEY PLAYERS), 2024     364

FIGURE 48            NUCLEAR MEDICINE SOFTWARE MARKET: COMPANY FOOTPRINT 365

FIGURE 49            NUCLEAR MEDICINE SOFTWARE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024                 374

FIGURE 50            GE HEALTHCARE: COMPANY SNAPSHOT (2024)                 382

FIGURE 51            SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)             390

FIGURE 52            KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2024)             396

FIGURE 53            LANTHEUS: COMPANY SNAPSHOT (2024)                 400

FIGURE 54            CANON MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT (2024)      405

FIGURE 55            MIRION TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)             409

FIGURE 56            RAYSEARCH LABORATORIES: COMPANY SNAPSHOT (2024)             438

FIGURE 57            SECTRA AB: COMPANY SNAPSHOT (2024)                 443

FIGURE 58            AGFA-GEVAERT GROUP: COMPANY SNAPSHOT (2024)    446

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧